Your browser doesn't support javascript.
loading
Engineering Novel 3D Models to Recreate High-Grade Osteosarcoma and its Immune and Extracellular Matrix Microenvironment.
Pierrevelcin, Marina; Flacher, Vincent; Mueller, Christopher G; Vauchelles, Romain; Guerin, Eric; Lhermitte, Benoît; Pencreach, Erwan; Reisch, Andreas; Muller, Quentin; Doumard, Layal; Boufenghour, Wacym; Klymchenko, Andrey S; Foppolo, Sophie; Nazon, Charlotte; Weingertner, Noelle; Martin, Sophie; Briandet, Claire; Laithier, Véronique; Di Marco, Antonio; Bund, Laurent; Obrecht, Adeline; Villa, Pascal; Dontenwill, Monique; Entz-Werlé, Natacha.
Affiliation
  • Pierrevelcin M; UMR CNRS 7021, Laboratory of Biomaging and Pathologies, Faculté de Pharmacie, 74 route du Rhin, Illkirch, 67405, France.
  • Flacher V; CNRS UPR3572, Laboratory I2CT - Immunology, Immunopathology and Therapeutic Chemistry, Strasbourg Drug Discovery and Development Institute (IMS), Institut de Biologie Moléculaire et Cellulaire, 2, Allée Konrad Roentgen, Strasbourg, 67084, France.
  • Mueller CG; CNRS UPR3572, Laboratory I2CT - Immunology, Immunopathology and Therapeutic Chemistry, Strasbourg Drug Discovery and Development Institute (IMS), Institut de Biologie Moléculaire et Cellulaire, 2, Allée Konrad Roentgen, Strasbourg, 67084, France.
  • Vauchelles R; UMR CNRS 7021, Laboratory of Biomaging and Pathologies, Faculté de Pharmacie, 74 route du Rhin, Illkirch, 67405, France.
  • Guerin E; Department of Cancer Molecular Genetics, Laboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, 1 avenue Molière, Strasbourg, 67098, France.
  • Lhermitte B; Pathology department, University Hospital of Strasbourg, 1 avenue Molière, Strasbourg, 67098, France.
  • Pencreach E; Department of Cancer Molecular Genetics, Laboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, 1 avenue Molière, Strasbourg, 67098, France.
  • Reisch A; UMR CNRS 7021, Laboratory of Biomaging and Pathologies, Faculté de Pharmacie, 74 route du Rhin, Illkirch, 67405, France.
  • Muller Q; CNRS UPR3572, Laboratory I2CT - Immunology, Immunopathology and Therapeutic Chemistry, Strasbourg Drug Discovery and Development Institute (IMS), Institut de Biologie Moléculaire et Cellulaire, 2, Allée Konrad Roentgen, Strasbourg, 67084, France.
  • Doumard L; CNRS UPR3572, Laboratory I2CT - Immunology, Immunopathology and Therapeutic Chemistry, Strasbourg Drug Discovery and Development Institute (IMS), Institut de Biologie Moléculaire et Cellulaire, 2, Allée Konrad Roentgen, Strasbourg, 67084, France.
  • Boufenghour W; CNRS UPR3572, Laboratory I2CT - Immunology, Immunopathology and Therapeutic Chemistry, Strasbourg Drug Discovery and Development Institute (IMS), Institut de Biologie Moléculaire et Cellulaire, 2, Allée Konrad Roentgen, Strasbourg, 67084, France.
  • Klymchenko AS; UMR CNRS 7021, Laboratory of Biomaging and Pathologies, Faculté de Pharmacie, 74 route du Rhin, Illkirch, 67405, France.
  • Foppolo S; UMR CNRS 7021, Laboratory of Biomaging and Pathologies, Faculté de Pharmacie, 74 route du Rhin, Illkirch, 67405, France.
  • Nazon C; Pediatric Onco-hematology unit, University Hospital of Strasbourg, 1 avenue Molière, Strasbourg, 67098, France.
  • Weingertner N; Pathology department, University Hospital of Strasbourg, 1 avenue Molière, Strasbourg, 67098, France.
  • Martin S; UMR CNRS 7021, Laboratory of Biomaging and Pathologies, Faculté de Pharmacie, 74 route du Rhin, Illkirch, 67405, France.
  • Briandet C; Pediatric Onco-hematology unit, Hospital of "Le Bocage"- University Hospital of Dijon, 1 bd Jeanne d'Arc, Dijon, 21079, France.
  • Laithier V; Pediatric Onco-hematology unit, University Hospital of Besançon, 3, boulevard A. Fleming, Besançon, 25030, France.
  • Di Marco A; Department of Orthopedic Surgery and Traumatology, University Hospital of Strasbourg, 1 avenue Molière, Strasbourg, 67098, France.
  • Bund L; Department of Pediatric Surgery, University Hospital of Strasbourg, 1 avenue Molière, Strasbourg, 67098, France.
  • Obrecht A; PCBIS Plate-forme de chimie biologique intégrative de Strasbourg, UMS 3286 CNRS, University of Strasbourg, Labex Medalis, 300 Bld Sébastien Brant, Illkirch, 67412, France.
  • Villa P; PCBIS Plate-forme de chimie biologique intégrative de Strasbourg, UMS 3286 CNRS, University of Strasbourg, Labex Medalis, 300 Bld Sébastien Brant, Illkirch, 67412, France.
  • Dontenwill M; UMR CNRS 7021, Laboratory of Biomaging and Pathologies, Faculté de Pharmacie, 74 route du Rhin, Illkirch, 67405, France.
  • Entz-Werlé N; UMR CNRS 7021, Laboratory of Biomaging and Pathologies, Faculté de Pharmacie, 74 route du Rhin, Illkirch, 67405, France.
Adv Healthc Mater ; 11(19): e2200195, 2022 10.
Article in En | MEDLINE | ID: mdl-36057996
ABSTRACT
Osteosarcoma (OS) is the most common primary bone cancer, where the overall 5-year surviving rate is below 20% in resistant forms. Accelerating cures for those poor outcome patients remains a challenge. Nevertheless, several studies of agents targeting abnormal cancerous pathways have yielded disappointing results when translated into clinic because of the lack of accurate OS preclinical modeling. So, any effort to design preclinical drug testing may consider all inter-, intra-, and extra-tumoral heterogeneities throughout models mimicking extracellular and immune microenvironment. Therefore, the bioengineering of patient-derived models reproducing the OS heterogeneity, the interaction with tumor-associated macrophages (TAMs), and the modulation of oxygen concentrations additionally to recreation of bone scaffold is proposed here. Eight 2D preclinical models mimicking several OS clinical situations and their TAMs in hypoxic conditions are developed first and, subsequently, the paired 3D models faithfully preserving histological and biological characteristics are generated. It is possible to shape reproducibly M2-like macrophages cultured with all OS patient-derived cell lines in both dimensions. The final 3D models pooling all heterogeneity features are providing accurate proliferation and migration data to understand the mechanisms involved in OS and immune cells/biomatrix interactions and sustained such that engineered 3D preclinical systems will improve personalized medicine.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Bone Neoplasms / Osteosarcoma Type of study: Prognostic_studies Limits: Humans Language: En Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Main subject: Bone Neoplasms / Osteosarcoma Type of study: Prognostic_studies Limits: Humans Language: En Year: 2022 Type: Article